nervous system
• in MOG33-35-treated mice
|
• increased in MOG33-35-treated mice
|
• severe vascular dystrophy of myelin in MOG33-35-treated mice
|
• in MOG33-35-treated mice
|
immune system
• mice treated with MOG33-35 exhibit more severe experimental autoimmune encephalomyelitis with decreased oligodendrocyte precursor cells, increased oligodendrocyte apoptosis, and severe vacuolar dystrophy of myelin and axonal damage compared with wild-type mice
|
cellular
• in MOG33-35-treated mice
|
• increased in MOG33-35-treated mice
|